Anti-idiotypic Antibodies against a Human Multiple Organ-reactive Autoantibody
Detection of Idiotopes in Normal Individuals and Patients with Autoimmune Diseases

Karim Essani, Jo Satoh, Bellur S. Prabhakar, Patrick R. McClintock, and Abner Louis Notkins
Laboratory of Oral Medicine, National Institute of Dental Research, National Institutes of Health, Bethesda, Maryland 20205

Abstract
We have recently isolated and characterized a human monoclonal autoantibody, MOR-h1 (multiple organ-reactive human 1), that reacts with antigens in multiple organs and have shown that this antibody binds to human growth hormone and a 35,000-mol wt protein. In the present study we generated three monoclonal anti-idiotypic antibodies (4E6, 3E5, and 3F6) against MOR-h1. These anti-idiotypic antibodies specifically reacted with MOR-h1 and not with 26 other multiple organ-reactive monoclonal IgM autoantibodies nor with pooled human IgM (myeloma proteins). The binding of the anti-idiotypic antibodies to MOR-h1 was inhibited by both human growth hormone and the 35,000-mol wt protein, which strongly suggests that these antibodies react with epitopes at or near the paratope on MOR-h1. The results of competitive binding experiments revealed that the epitope recognized by 4E6 is distinct from that recognized by 3E5 and 3F6. Using these anti-idiotypic antibodies, lymphocytes and sera from normal individuals were tested for the presence of the 4E6 and 3E5/3F6 idiotypes. By indirect immunofluorescence, the 4E6 idiotope was detected on an average of 1.1% of normal circulating B lymphocytes, and by enzyme-linked immunosorbent assays, the 4E6 and to a lesser extent the 3E5/3F6 idiotopes were found on IgG molecules in sera of normal individuals. In spite of the expression of idiotopes known to be present on MOR-h1, no MOR-h1-like antibody activity was detected in normal sera. Examination of sera from patients with several autoimmune diseases failed to show an increased expression of the 4E6 idiotope as compared with normal controls. These data suggest that anti-idiotypic antibody 4E6 recognizes a public idiotope, the expression of which is not restricted to autoimmune disease.

Introduction
Idiotype determinants on antibodies and cells and their recognition by anti-idiotype antibodies have been given a prominent role in current theories of immunoregulation (1–4). The idiotopes expressed on autoantibodies are of particular interest since it has been suggested that autoantibodies may represent failures of, or gaps in, the immunoregulatory network. Recent studies in mice (5) and in humans (6) suggested that certain idiotypes are closely associated with particular autoimmune disorders. It also has been speculated that a limited number of families of immunoglobulins may be involved in autoimmunity (7). If this turns out to be the case, then anti-idiotype antibodies may serve as useful probes to quantitate the level of expression of idiotopes in both normal individuals and patients.

Recently we prepared a hybridoma secreting a human monoclonal autoantibody, designated MOR-h1 (multiple organ-reactive human 1) (8). This antibody (IgM-) reacts with antigens in several different organs including the pituitary, thyroid, pancreas, and stomach. Using an MOR-h1 immunoaffinity column we have isolated the autoantigens (i.e., 35,000 and 21,000-mol wt proteins) with which this autoantibody reacts. The 35,000-mol wt protein is present in the pituitary, thyroid, and stomach; and the 21,000-mol wt protein, which was shown to be human growth hormone (hGH), is found only in the pituitary. We now report the preparation and characterization of three monoclonal antibodies directed against idiotypic determinants at or near the paratope of MOR-h1. Using these anti-idiotype antibodies we have studied the expression of the corresponding idiotopes on immunoglobulins in the sera of normal individuals and patients with autoimmune diseases.

Methods
Human monoclonal autoantibodies. The procedure for the preparation of MOR-h1 and 26 other human monoclonal multiple organ-reactive (MOR) antibodies has already been described (8–9). All of these autoantibodies are of the IgM class. Some of these antibodies were prepared by fusing human peripheral B lymphocytes with either human or mouse myeloma cells (8). Others were prepared by immortalizing peripheral B lymphocytes with Epstein-Barr virus (9).

Purification of MOR-h1. MOR-h1 was purified using an immunoaffinity column, which was prepared by coupling the IgG fraction of sheep anti-human IgM to CNBr-activated Sepharose-4B (Pharmacia Fine Chemicals, Piscataway, NJ) as previously described (10). The adsorbed MOR-h1 was eluted with 0.1 M glycine-HCl (pH 2.5); the pH of the eluate was adjusted to 7.5 before exhaustive dialysis against deionized water, and the material was lyophilized. The purity of MOR-h1 was tested by SDS-polyacrylamide gel electrophoresis, and only two bands having the apparent molecular weights of α- and ε-chains were detected. The purified MOR-h1 was also checked for immunological reactivity with synthetic hGH (kindly provided by Genentech, Inc., South San Francisco, CA) and a 35,000-mol wt polypeptide (from human gastric mucosa) by employing an enzyme-linked immunosorbent assay (ELISA) as described earlier (10).

Preparation, screening, and purification of monoclonal anti-idiotype antibodies. Balb/c AnN mice received five weekly, intraperitoneal injections of 100 µg of affinity-purified MOR-h1. 3 d after the last injection, splenic lymphocytes were fused with P,653 Ag8 myeloma cells using

1. Abbreviations used in this paper: ELISA, enzyme-linked immunosorbent assay; FITC, fluorescein isothiocyanate; hGH, human growth hormone; IDDM, insulin-dependent diabetes mellitus; MOR, multiple organ-reactive; MOR-h1, multiple organ-reactive human 1 autoantibody; RIA, radioimmunoassay; SLE, systemic lupus erythematosus; TRITC, tetramethylrhodamine isothiocyanate.

Dr. Satoh’s present address is The Third Department of Internal Medicine, Tohoku University School of Medicine, 1-1 Seiryo-machi, Sendai, Miyagi 980, Japan.

Received for publication 25 February 1985.
50% polyethylene glycol at neutral pH, essentially as described by Köhler and Milstein (11). The fused cells were plated in 96-well tissue culture plates and incubated at 37°C. Supernatants from cultures grown to confluency were initially screened for anti-MOR-h1 and anti-human IgM antibody by ELISA in which Immulon II plates (Dynatech Laboratories, Alexandria, VA) were coated with either MOR-h1 or pooled human myeloma IgM. The bound monoclonal IgG was detected using peroxidase-labeled goat anti-mouse γ-chain-specific antibodies. The positive wells showing reactivity with MOR-h1, but not with pooled human IgM, were cloned using the end point dilution method (12). The three hybridomas thus obtained were designated 4E6, 3E5, and 3F6.

**Immunoreagents.** All antiimmunoglobin reagents, including peroxidase conjugates and fluorescently labeled immunoglobulins or fragments, and pooled human myeloma IgM were obtained from Coover Biomedical, Malvern, PA.

ELISA. Except where indicated, the following general procedures for ELISA were used. Affinity-purified antigens or antibodies (1 μg/well) were coated on Immulon II plates (Dynatech Laboratories) in carbonate-bicarbonate buffer (pH 9.6) overnight at 4°C. In some experiments, MOR-h1 from hybridoma medium was bound to plates previously coated with affinity-purified IgA (γ-chain-specific) to selectively retain MOR-h1 on the Immulon II wells. Duplicate test samples were diluted in phosphate-buffered saline (PBS) containing 0.1% gelatin and 0.05% Tween 20, and the plates were incubated with samples for 2 h at room temperature. At each step and after the final incubation, the plates were washed six times with PBS containing 0.05% Tween 20 (PBS-Tween). Peroxidase-conjugated antibodies diluted 1:300 with PBS containing 0.1% gelatin were used to detect antigens or antibodies. Peroxidase activity was measured using H2O2 and ortho-phenylenediamine, and the optical density (OD) at 492 nm was read with a microplate reader (Flow Laboratories, McLean, VA).

Radioiodination of antibodies and solid-phase radioimmunoassays (RIAs). Affinity-purified monoclonal antibodies were iodinated by a modification of the chloramine T method (13). The reaction mixture was then chromatographed on a Sephadex G-25M column (Pharmacia Fine Chemicals) to separate the protein from free radioidine. The iodinated proteins were then dialyzed overnight against PBS at 4°C, and were tested for their immunological reactivity in a solid-phase RIA. At least 90% of the input counts per minute (cpm) bound to MOR-h1, while only 3–5% of the input cpm reacted with gelatin-coated wells which served as the negative control.

For competitive binding experiments Immulon II removable wells (Dynatech Laboratories) were coated with 1 μg/well of affinity-purified MOR-h1 as described for ELISA. Following washing, 0.1% gelatin in PBS was added to each well, and incubated for 2 h at room temperature to block the remaining protein binding sites on the wells. Serial twofold dilutions of each monoclonal anti-idiotypic antibody (initial concentration, 1 mg/ml) were made in PBS containing 0.1% gelatin. To each of these dilutions 125I-anti-idiotypic antibody was added. An aliquot of the mixture of labeled and unlabeled monoclonal antibodies (50 μl) was then added to wells coated with MOR-h1. Following 2 h of incubation at 37°C, the wells were washed six times with PBS-Tween and the radioactivity was measured in a Biogamma II counter (Beckman Instruments, Inc., Fullerton, CA). Percent inhibition was computed as 100 times the cpm bound in the presence of inhibitor divided by the cpm bound in the absence of inhibitor.

Detection of 4E6 idiotope-bearing B lymphocytes in the peripheral blood. Mononuclear cells were separated from heparinized human blood by density centrifugation, and the B lymphocyte-enriched population was obtained after depletion of the T lymphocytes by rosetting with 2-aminoethylisothiouronium bromide hydrobromide-treated sheep erythrocytes (14). The cells thus obtained were washed with cold PBS containing 0.1% bovine serum albumin (BSA) and 0.01% sodium azide. The cells (1 × 10⁶) were resuspended in 0.2 ml (25 μg/ml) of either 4E6 or an IgG(κ) mouse myeloma (MOPC-21) and incubated for 30 min on ice. After washing in PBS the cells were reacted with a mixture of tetramethylrhodamine isothiocyanate (TRITC)-conjugated F(ab')₂ fragment of goat anti-human immunoglobulins (IgA + IgG + IgM) and fluorescein isothiocyanate (FITC)-conjugated F(ab')₂ fragment of sheep anti-mouse IgG (that did not cross react with human IgG) for 30 min on ice. The cells were washed and fixed with 1% paraformaldehyde in PBS overnight at 4°C, and then viewed with an epifluorescence microscope. The cells stained with TRITC (i.e., surface Ig-positive B lymphocytes) or the cells stained with both TRITC and FITC (i.e., 4E6-reacting B lymphocytes) were counted under rhodamine and fluorescein filters, respectively. At least 500 surface Ig-positive cells were counted, and the percentage of 4E6-reacting B lymphocytes out of the total B lymphocytes was calculated. Neither MOPC-21 nor the FITC-labeled sheep anti-mouse IgG by itself stained B lymphocytes.

Detection by ELISA of 4E6, 3E5, and 3F6 idiotopes in human sera. Human sera diluted 1:10 with PBS containing 2% BSA and 0.05% Tween-20 were added to wells that had been coated with 1 μg/well of affinity-purified 4E6, 3E5, 3F6, or MOPC-21, and the plates were incubated overnight at 4°C. After washing, the plates were incubated for 5 h at room temperature or overnight at 4°C with peroxidase-conjugated goat anti-human IgG (γ-chain-specific) previously absorbed with both MOPC-21 and the appropriate anti-idiotypic antibody. After washing the substrate was added and the OD₅₅₀ of each sample was measured. Pilot experiments with peroxidase-conjugated goat anti-human IgM (μ-chain-specific) yielded high background activity preventing its use to reliably detect the 4E6, 3E5, and 3F6 idiotopes on human IgM in sera.

**Results**

**Preparation of monoclonal anti-idiotypic antibodies against MOR-h1 and their reactivities with human monoclonal antibodies.** Hybridomas secreting anti-idiotypic antibodies were prepared by fusing spleen cells from MOR-h1-immunized BALB/c mice with P3 653 Ag8 myeloma cells. Two independent fusions (480 wells each) yielded a total of seven wells that reacted with MOR-h1. After further testing and cloning, three of these (designated 4E6, 3E5, and 3F6) were found to react specifically with MOR-h1 and not with pooled human IgM. All three were of the IgG(κ) type. To assess the specificity of these anti-idiotypic antibodies, ELISA plates coated with 27 different human monoclonal IgM autoantibodies were incubated with 4E6, 3E5, and 3F6. All of the monoclonal anti-idiotypic antibodies reacted strongly with MOR-h1 but gave negligible reactions with the other 26 monoclonal IgMs and with pooled human myeloma IgM (Fig. 1).

The preceding experiment showed that our mouse monoclonal IgG anti-idiotypic antibodies reacted specifically with MOR-h1. The formal possibility existed, however, that MOR-h1 had an affinity for mouse IgG. To test this possibility MOR-h1 was incubated with several mouse monoclonal IgGs including the anti-idiotypic antibody, 4E6 (Table I). MOR-h1 reacted strongly with 4E6, but did not react with any of the other mouse monoclonal IgGs.

**Inhibition of binding of MOR-h1 to anti-idiotypic antibodies by hGH and 35,000-mol wt protein.** MOR-h1 has been shown to react with both hGH and a 35,000-mol wt protein found in various human tissues (10). If our anti-idiotypic antibodies are directed against a site at or near the paratope of MOR-h1, then hGH and the 35,000-mol wt protein should inhibit the binding of MOR-h1 to the anti-idiotypic antibodies. Fig. 2A shows that incubation of MOR-h1 with hGH or 35,000-mol wt protein inhibited its binding to 4E6-coated plates. The degree of inhibition was related to the concentration of the ligands. These data also suggest, but do not prove, that the affinity of MOR-h1 for hGH is less than its affinity for the 35,000-mol wt protein. BSA used as a control showed no reactivity except at very high concentrations. Similar results were obtained when a second mono-
Antibody and bodies.

MOR-hI and other monoclonal antibodies. Confirm that all anti-human oxidase-conjugated in the Table of MOR-hI.

Table I. Interaction of MOR-hI with Mouse Monoclonal Anti-idiotypic Antibody and Other Monoclonal Mouse IgGs*

<table>
<thead>
<tr>
<th>Antibodies‡</th>
<th>Isotype§</th>
<th>MOR-hI</th>
<th>Anti-mouse IgG3</th>
</tr>
</thead>
<tbody>
<tr>
<td>4E6</td>
<td>IgG1</td>
<td>797</td>
<td>870</td>
</tr>
<tr>
<td>183-4</td>
<td>IgG1</td>
<td>42</td>
<td>670</td>
</tr>
<tr>
<td>187-1</td>
<td>IgG2a</td>
<td>3</td>
<td>894</td>
</tr>
<tr>
<td>204-4</td>
<td>IgG2a</td>
<td>5</td>
<td>853</td>
</tr>
<tr>
<td>356-1</td>
<td>IgG2a</td>
<td>20</td>
<td>850</td>
</tr>
<tr>
<td>286-1</td>
<td>IgG2b</td>
<td>30</td>
<td>782</td>
</tr>
<tr>
<td>9-4</td>
<td>IgG3</td>
<td>48</td>
<td>754</td>
</tr>
<tr>
<td>PBS</td>
<td>—</td>
<td>25</td>
<td>11</td>
</tr>
</tbody>
</table>

* ELISA plates were coated with the IgG fraction of sheep anti-mouse IgG. 0.1 ml of the culture supernatant from each mouse hybridoma was added to duplicate wells, and the plates were incubated to fix the monoclonal IgG onto the plates. After washing, 0.1 ml of MOR-hI culture supernatant was added and the MOR-hI bound to mouse IgG was detected by peroxidase-conjugated goat anti-human IgM (μ-chain-specific).

‡ Except 4E6, all others were anti-Coxsackie B4 monoclonal antibodies (15).
§ Isotype was determined by immunodiffusion with specific typing sera.

The reaction of peroxidase-conjugated anti-mouse IgG (γ-chain-specific) with the antibody-coated plates was used to show that all of the mouse monoclonal IgGs were present in the wells in approximately equal amounts.

Figure 1. Reactivities of monoclonal anti-idiotypic antibodies with MOR-hI and other monoclonal human IgMs. Duplicate wells in an ELISA plate were coated with 27 human monoclonal IgMs including MOR-hI or pooled human myeloma IgM as described in Methods. The plates were washed and then incubated with anti-idiotypic antibodies. (a) MOR-hI, (b) mean of 26 human MOR antibodies, (c) pooled human myeloma IgM Bar shows 1 SD. Because variations in the amount of human IgM bound to the wells might cause variability in the reactions with the anti-idiotypic antibodies, the reaction of peroxidase-conjugated anti-human IgM (μ-chain-specific) was used to confirm that all wells contained approximately equal amounts of IgM.

clonal anti-idiotypic antibody, 3F6, was used (Fig. 2 B). In this case, hGH and the 35,000-mol wt protein inhibited the binding of MOR-hI to 3F6 over an even greater range of ligand concentrations. Taken together, these experiments show that both 4E6 and 3F6 are ligand-inhibitable.

Evidence for ligand inhibition was also obtained in a solid-phase RIA in which the order of adding the reagents was reversed. Plates were coated with MOR-hI, incubated with varying concentrations of hGH, and then the binding of 125I-labeled 4E6, 3F6, and polyclonal anti-human IgM was measured. As seen in Fig. 3 the binding of the anti-idiotypic antibodies, but not polyclonal anti-human IgM was inhibited.

Inhibition of binding of hGH to MOR-hI by anti-idiotypic antibodies was detected using peroxidase-conjugated goat anti-human IgM (μ-chain-specific). Maximum binding (100%) corresponded to ~1,200 OD₄₅₀ (×10³) and nonspecific binding (0%) was always <100 OD₄₅₀ (×10³).

Figure 2. Inhibition of binding of anti-idiotypic antibodies by hGH and 35,000-mol wt protein as measured by ELISA. Culture supernatant containing 2 μg/ml of MOR-hI was mixed with varying concentrations of hGH (●), 35,000-mol wt protein (●), or BSA (●), and incubated overnight at 4°C. The mixtures were then added to ELISA plates coated with affinity-purified anti-idiotypic antibodies 4E6 (●) or 3F6 (●). Binding of MOR-hI to the anti-idiotypic antibodies was detected using peroxidase-conjugated goat anti-human IgM (μ-chain-specific). Maximum binding (100%) corresponded to ~1,200 OD₄₅₀ (×10³) and nonspecific binding (0%) was always <100 OD₄₅₀ (×10³).

Figure 3. Inhibition of binding of anti-idiotypic antibodies to MOR-hI by hGH as measured by RIA. Immunol II wells were coated with affinity-purified MOR-hI, and various concentrations of purified hGH in PBS containing 0.1% gelatin were added to duplicate wells and incubated at 4°C overnight. The wells were washed and 125I-4E6 (●), 125I-3F6 (●), or 125I polyclonal anti-human IgM (●) was added and incubated at 37°C for 2 h. Following extensive washing, radioactivity was measured. Maximum binding (100%) corresponded to ~6,000 cpm and nonspecific binding (0%) was always <175 cpm.
antibody 4E6. If 4E6 is specific for an epitope located at the antigen binding site on MOR-h1, then the binding of hGH to MOR-h1 should be inhabitable by the anti-idiotypic antibody. Fig. 4 shows that 4E6 blocks the binding of hGH to MOR-h1, whereas a control mouse monoclonal IgG antibody had no effect. Together with data from Figs. 2 and 3, these results show that anti-idiotypic antibody 4E6 is directed against a site at or near the paratope on MOR-h1.

Monoclonal anti-idiotypic antibodies recognize different epitopes on MOR-h1. The possibility that the different anti-idiotypic antibodies might be recognizing different epitopes was evaluated in blocking experiments. As shown in Fig. 5A, the binding of 125I-labeled 4E6 to MOR-h1 was inhibited by unlabeled 4E6, but not by 3E5 or 3F6. In contrast, the binding of 125I-labeled 3E5 and 125I-labeled 3F6 to MOR-h1 was inhibited by both 3E5 and 3F6, but not by 4E6 (Fig. 5B and C, respectively). Thus antibody 4E6 recognizes an epitope on MOR-h1 that is different from that recognized by 3E5 and 3F6, whereas 3E5 and 3F6 appear to be recognizing the same epitope on the MOR-h1 molecule.

Detection of 4E6 idiotope-bearing B lymphocytes in peripheral blood. Having characterized the monoclonal anti-idiotypic antibodies, we wanted to see if the idiotopes with which they reacted were present on immunoglobulin-bearing B cells. Peripheral blood B lymphocytes were examined for the presence of 4E6 idiotope-bearing B cells by indirect immunofluorescence with anti-idiotypic antibody 4E6. From each individual at least 500 surface immunoglobulin-bearing cells were counted. In 13 out of 14 individuals (Table II), between 0.2 and 3.0% of the B lymphocytes expressed the 4E6 idiotope. Neither MOPC-21 nor sheep anti-mouse IgG stained any of the human B cells.

Detection of 4E6 idiotope-bearing immunoglobulins in human sera. Since up to 3% of B cells from normal individuals were found to bear the 4E6 idiotope, sera from normal individuals were tested for the presence of this idiotope. Fig. 6 shows that close to 85% of 130 human sera reacted with anti-idiotypic antibody 4E6 (i.e., 2 SD above control). Considerable quantitative differences, however, were found among individuals. In the same individual, expression of the 4E6 idiotope remained fairly constant with time (Fig. 7).

Comparison of the expression of 4E6 and 3E5/3F6 idiotopes in human sera. The presence of the 4E6 idiotope in human sera raised the question as to whether the 3E5 and 3F6 idiotopes also were expressed. Plates were coated with equal concentrations (1 µg/well) of the anti-idiotypic antibodies (4E6, 3E5, and 3F6) and then incubated with MOR-h1 or a panel of normal human sera. As seen in Fig. 8, MOR-h1 reacted to approximately the same extent with all three anti-idiotypic antibodies. The panel of human sera also reacted with anti-idiotypic antibodies 3E5 and 3F6, but to a much lesser extent than with 4E6. One possible explanation for the differences in reactivity is that the 4E6 idiotope may be present on molecules that do not always possess the 3E5 and 3F6 idiotopes.

Sera positive for the 4E6 idiotope do not react with hGH, 35,000-mol wt protein, or human tissues. The widespread expression of the 4E6 idiotope suggested that at least some sera might contain immunoglobulins bearing paratopes similar in reactivity to MOR-h1. Five sera that showed different degrees of expression of the 4E6 idiotope were tested for their ability to react with hGH, the 35,000-mol wt protein, and sections of normal human tissues. As seen in Table III, none of the sera showed appreciable reactivity with any of the antigens tested. In addition, we tested the ability of different concentrations (from 1 µg to 1 mg/ml) of hGH to inhibit the binding of these sera to 4E6-coated wells in a competitive inhibition assay. hGH inhibited the binding of MOR-h1 to 4E6 in a concentration-dependent manner, but failed to significantly inhibit the binding of these sera to 4E6 (results not shown).

Expression of the 4E6 idiotope in patients with autoimmune disorders. Because the MOR-h1 hybridoma was originally prepared from the lymphocytes of a patient with insulin-dependent diabetes mellitus (IDDM) and because MOR-h1 reacts with autoantigens, we wanted to see if the 4E6 idiotope might be expressed to a greater extent in sera from patients with autoimmune diseases than in sera from normal individuals. Serum or plasma was obtained from 85 normal individuals, 24 patients with IDDM, 41 patients with IDDM and Hashimoto's thyroiditis, 49

---

**Figure 4.** Inhibition of binding of hGH to MOR-h1 by anti-idiotypic antibody 4E6. Anti-idiotypic antibody 4E6 (○) or control antibody 356-1 (●) (a mouse monoclonal IgG which does not bind to MOR-h1) (15) was added to MOR-h1-coated wells and incubated for 2 h at room temperature. Following washing, 2 µg/well of synthetic hGH (kindly provided by Gentech, Inc., South San Francisco, CA) was added to each well and incubated as described in Methods. After washing, 0.1 ml of rabbit anti-hGH serum (kindly provided by the National Pitutary Agency, Baltimore, MD) diluted 1:2,000 was added to each well. Rabbit IgG binding to hGH was detected by peroxidase-conjugated goat anti-rabbit IgG and the percent inhibition of hGH-binding was then calculated. Maximum binding (100%) corresponded to ~1,600 OD492 (×10⁴) and nonspecific binding (0%) was always <50 OD492 (×10⁴).

**Figure 5.** Monoclonal anti-idiotypic antibodies recognize different epitopes on MOR-h1. Immulon II plates were coated with affinity-purified MOR-h1 (1 µg/well). Various concentrations of unlabeled inhibitors, 4E6 (A), 3E5 (△), 3F6 (●), or 356-1 (●) were mixed with 125I-4E6 (○), 125I-3F6 (□) or 125I-3E5 (△). The mixtures were added to the MOR-h1-coated wells in duplicate. The plates were incubated for 2 h at 37°C and washed extensively; the radioactivity was measured and percent inhibition calculated. Maximum binding (100%) corresponded to ~6,500 cpm and nonspecific binding (0%) was always <150 cpm.
Table II. Frequency of 4E6 Idiotope-bearing B Lymphocytes in Peripheral Blood Detected by Anti-idiotypic (4E6) Antibody*

<table>
<thead>
<tr>
<th>Individual</th>
<th>Percent 4E6 idiotope-bearing B lymphocytes‡</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>2</td>
<td>0.2</td>
</tr>
<tr>
<td>3</td>
<td>0.2</td>
</tr>
<tr>
<td>4</td>
<td>0.4</td>
</tr>
<tr>
<td>5</td>
<td>0.5</td>
</tr>
<tr>
<td>6</td>
<td>0.7</td>
</tr>
<tr>
<td>7</td>
<td>0.8</td>
</tr>
<tr>
<td>8</td>
<td>1.0</td>
</tr>
<tr>
<td>9</td>
<td>1.2</td>
</tr>
<tr>
<td>10</td>
<td>1.5</td>
</tr>
<tr>
<td>11</td>
<td>1.6</td>
</tr>
<tr>
<td>12</td>
<td>2.0</td>
</tr>
<tr>
<td>13</td>
<td>2.8</td>
</tr>
<tr>
<td>14</td>
<td>3.0</td>
</tr>
<tr>
<td>Average</td>
<td>1.1</td>
</tr>
</tbody>
</table>

* Determined by indirect immunofluorescence as described in Methods.
‡ At least 500 surface immunoglobin-bearing cells were counted in each sample.

patients with only Hashimoto's thyroiditis, and 47 patients with rheumatological disorders (predominantly systemic lupus erythematosus, SLE). As shown in Fig. 9, except for a few unusually high values for sera from patients with both IDDM and thyroiditis, no discernible differences were detected among the groups of sera.

Discussion

We have generated three murine monoclonal anti-idiotypic antibodies against a human monoclonal autoantibody (MOR-h1) that reacts with multiple organs (8, 10). It is generally accepted that an anti-idiotypic antibody is directed against the paratope if it is ligand-inhibitable (16, 17). Our anti-idiotypic antibodies reacted specifically with MOR-h1, but not with 26 other mono-

clonal MOR autoantibodies nor with pooled human myeloma IgM. Blocking experiments clearly demonstrated that the interaction of purified hGH and the 35,000-mol wt protein with
Table III. Reactivity of Sera Expressing the 4E6 Idiotope with hGH, the 35,000-mol wt Protein, and Normal Tissues

<table>
<thead>
<tr>
<th>Sera</th>
<th>Reactivity of sera with 4E6*</th>
<th>Reactivity of sera with hGH*</th>
<th>Reactivity of sera with 35,000-mol wt protein*</th>
<th>Tissue†</th>
</tr>
</thead>
<tbody>
<tr>
<td>No. 80</td>
<td>46§</td>
<td>42</td>
<td>85</td>
<td>82</td>
</tr>
<tr>
<td>No. 67</td>
<td>122</td>
<td>39</td>
<td>89</td>
<td>72</td>
</tr>
<tr>
<td>No. 32</td>
<td>214</td>
<td>49</td>
<td>96</td>
<td>99</td>
</tr>
<tr>
<td>No. 95</td>
<td>594</td>
<td>22</td>
<td>44</td>
<td>42</td>
</tr>
<tr>
<td>No. 55</td>
<td>692</td>
<td>175</td>
<td>185</td>
<td>176</td>
</tr>
<tr>
<td>PBS</td>
<td>61</td>
<td>82</td>
<td>111</td>
<td>108</td>
</tr>
<tr>
<td>MOR-h1</td>
<td>1,026</td>
<td>71</td>
<td>516</td>
<td>1,099</td>
</tr>
</tbody>
</table>

* Plates were coated with 1 μg of 4E6, 1 μg hGH, 0.5 μg of 35,000-mol wt protein per well, or PBS without protein (PBS). Sera were diluted 1:5 (MOR-h1 was used at 26 μg/ml) in PBS, added to the coated wells, and incubated and washed as described in Methods. The bound immunoglobulins were then detected by peroxidase-conjugated anti-human immunoglobulins (IgA + IgG + IgM) or anti-human IgM (μ-chain-specific), respectively.

§ Sera were screened on sections of human thyroid, pituitary, stomach, and pancreas by indirect immunofluorescence using FITC-conjugated anti-human immunoglobulins (IgA + IgG + IgM) as described previously.

§ OD₉₀² (×10³)

MOR-h1 inhibited the binding of MOR-h1 to the anti-idiotypic antibodies, and conversely, the interaction of anti-idiotypic antibody 4E6 with MOR-h1 inhibited the binding of hGH to MOR-h1. We have also shown that both hGH and the 35,000-mol wt protein can compete with anti-idiotypic antibodies for binding to MOR-h1 in a concentration-dependent manner. These experiments provide compelling evidence that the anti-idiotypic antibodies are reacting specifically either with the paratope or with an epitope very close to the paratope on MOR-h1.

Based on competitive binding experiments, our monoclonal anti-idiotypic antibodies appear to recognize two different idiotopes on MOR-h1 (Fig. 5). Antibody 4E6 defines an idiotypic determinant on MOR-h1 which is clearly distinct from the site(s) recognized by antibodies 3E5 and 3F6. Since antibodies 3E5 and 3F6 compete with each other, it appears that they may be recognizing the same idiotope which we have designated the 3E5/3F6 idiotope. On immunoglobulin molecules in human sera, in contrast to MOR-h1, the 4E6 idiotope appears to be expressed independently of the 3E5/3F6 idiotope (Fig. 8).

Other experiments were carried out in an attempt to further characterize the anti-idiotypic antibodies. Since monoclonal autoantibody MOR-h1 (idiotype antibody-Abi) reacts with hGH and since some anti-idiotypic antibodies (Ab2) are internal images of the paratope with which they react (18–21), we tested anti-idiotypic antibody 4E6 for its ability to bind to hGH receptors. Even at a high concentration, antibody 4E6 (1 mg/ml) failed to inhibit the binding of growth hormone to its receptor on IM-9 cells (K. Essani, unpublished observations) (22). Others have shown that immunization with "internal image" anti-idiotypic antibodies yields anti-anti-idiotypic antibodies (Ab3), some of which can bind the antigen recognized by the original antibody (Ab1) (23–25). Preliminary experiments indicate that rabbits immunized with antibody 4E6 acquire MOR-h1 antibody activity in their sera (K. Essani and J. Satoh, unpublished observations).

Having characterized the 4E6 anti-idiotypic antibody, we used it to study the expression of the 4E6 idiotope on human B lymphocytes. Our experiments revealed that the 4E6 idiotope is expressed on an average of 1.1% of normal B lymphocytes. This unexpectedly high frequency suggests that the 4E6 idiotope is expressed not only on B lymphocytes secreting MOR-h1 but also on lymphocytes with other specificities. Moreover, the majority of normal sera contained 4E6-idiotope bearing immunoglobulins in greater or lesser quantities. Despite the presence of the 4E6 idiotope, these sera did not possess MOR-h1-like antibody activity when tested against hGH, the 35,000-mol wt protein, or human tissues known to react with MOR-h1. In addition, in a competition assay, hGH failed to inhibit the binding of human sera to 4E6. Taken together, the data suggest that the 4E6 idiotope represents a public specificity on immunoglobulins and is not limited to just MOR-h1.

Our findings are consistent with the idea that idiotopes present on autoantibodies are not necessarily restricted to antibodies with the same antigen-binding specificity (26–28). In fact, anti-idiotypic antibodies are known to cross-react with other immunoglobulins at sites not located at or near the antigen-binding domain (29, 30) and even at sites on nonimmunoglobulin mol...
ecules (31). In this connection, Datta et al. (28) reported that normal mice without detectable amounts of anti-DNA antibody in their sera, expressed idiotopes that reacted with anti-idiotypic antibodies raised against anti-DNA antibodies. These idiotopes were expressed on both DNA-binding and non-DNA-binding immunoglobulins in the sera of normal mice. Anti-idiotypic antibodies (Ab2) also may recognize idiotopes on the parallel set of immunoglobulins (Ab3) which may not bind to the antigen that induces Ab1. In some cases, these idiotopes may be involved in immune regulation (1, 2).

It has been suggested that anti-idiotypic antibodies might serve as probes for detecting idiotopes that might be specifically expressed in certain autoimmune diseases (28, 32–35). It is clear, however, from both the present work and recent studies from other laboratories (28, 35) that idiotypic markers thought to be related to autoimmune diseases are expressed in normal individuals and that antibodies bearing these markers do not necessarily have the ability to bind autoantigens. This raises a number of fundamental questions about the clinical usefulness of anti-idiotypic antibodies as probes to study autoimmune diseases. First, do all patients with a specific autoimmune disease, or at risk of developing that disease, express the same idiotope? Second, is the specific monoclonal antibody used to make the anti-idiotypic antibody present and active in the disease or is it simply part of the normal B cell repertoire (36)? Third, is the idiotope of interest expressed only on autoantibodies characteristic of that disease or is it more generally expressed and present on otherwise unrelated molecules? If the former, its expression may be easily quantitated and correlated with clinical disease activity. If the latter, the background reactivity may preclude meaningful quantitation. Perhaps some of these potential problems can be resolved, at least in part, by developing a large panel of anti-idiotypic antibodies directed against a spectrum of disease-specific monoclonal autoantibodies.

Acknowledgments

We thank Dr. Fred Miller and Dr. Paul Plotz for providing sera from patients with systemic lupus erythematosus, Dr. Atsusi Muraguchi for helpful discussions concerning the immunostaining of B cells, and Ms. Denise Haller for the preparation of the manuscript.

References


